Research programme: plasmin inhibitors - Omeros

Drug Profile

Research programme: plasmin inhibitors - Omeros

Alternative Names: OMS 616

Latest Information Update: 09 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of California at Los Angeles
  • Developer Omeros Corporation
  • Class Proteins
  • Mechanism of Action Blood coagulation factor modulators; Plasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemorrhage

Most Recent Events

  • 16 Mar 2017 Omeros Corporation has patent protection for plasmin inhibitors in USA and ex-US countries
  • 23 May 2014 Preclinical development is ongoing in the USA
  • 03 May 2012 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top